Further details on selected drug discovery programmes for the treatment of Neurodegenerative diseases

New Targets from the Treatment of Parkinson’s Disease

Two publicly available Parkinson’s Disease (“PD”) datasets using C4XD’s proprietary target discovery technology Taxonomy3® have identified multiple novel disease associated genes in discrete patient sub-groups that could potentially provide an opportunity in stratified medicine. Informatic analysis of proprietary genes discovered with Taxonomy3®, together with known genetic susceptibility genes, has flagged new pathways relevant to the disease aetiology: identification of such disease-relevant pathways is a pivotal step in drug discovery.

We initiated the first drug discovery evaluation stage programme in PD from this analysis and continue to work through the other novel drug targets from the genes we have discovered to provide the biological validation ahead of initiating further drug discovery programmes.

Working in collaboration with e-Therapeutics we will apply the power of e-Therapeutics’ proprietary Network-Driven Drug Discovery (“NDD”) platform with the results from Taxonomy3® to identify new treatment strategies, molecular targets and ultimately, novel drugs PD

Working in collaboration with PhoreMost, we advance our work in PD using its SITESEEKER screening platform to validate novel targets already identified by Taxonomy3® and provide chemical starting points to launch drug discovery programmes.

These collaborations in combination with our own novel target discovery platform will enable us to gain a strong foothold in the PD drug discovery field.

New Targets from the Treatment of Alzheimer’s Disease

Following the significant genetic discoveries in Parkinson’s Disease using our Taxonomy3® platform our analysis of an Alzheimer’s Disease dataset has identified discrete patient sub-groups that have not been described previously and characterisation of the novel genetic associations are underway. A short-list of potential targets from this analysis has been prioritised and is being refined ahead of the initiation of new drug discovery programmes.